EyePoint Pharmaceuticals
Présence
EyePoint Pharmaceuticals est une société cotée sous le symbole boursier EYPT (US).
Dirigeants
Voir l'organigramme avec ses 20 principaux dirigeants
Biographies les plus recherchées chez EyePoint Pharmaceuticals
- Jay Duker, President and Chief Executive Officer
- Wendy DiCicco, Director
- Nancy Lurker, Executive Vice Chairman of the Board
Changements de dirigeants chez EyePoint Pharmaceuticals
- Ramiro Ribeiro, a rejoint l'entreprise comme Chief Medical Officer (publié le 5 mars 2024).
- Dario Paggiarino, Senior Vice President & Chief Medical Officer, a quitté l'entreprise (publié le 5 mars 2024).
- Stuart Duty, a rejoint l'entreprise comme Director (publié le 17 octobre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez EyePoint Pharmaceuticals.
Équipements médicaux
EyePoint Pharmaceuticals a 980 concurrents dont Philips (Pays—Bas), Medtronic (Irlande) et Thermo Fisher Scientific (Etats—Unis).
Actualités en fusion/acquisition en Équipements médicaux.
- Medigus changera son nom en Xylo Technologies le Apr 12, 2024. (publié le 12 avril 2024).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (publié le 6 avril 2024).
- Carlsmed vient d'annoncer une levée de fonds de 52 millions de dollars. (publié le 22 mars 2024).
Contacts en Équipements médicaux
- Don Abbey - Executive Vice President, Global Business Services, Information Technology, Quality and Regulatory Affairs chez DexCom
- Marc Casper - Chairman of the Board, President and Chief Executive Officer chez Thermo Fisher Scientific
- Frank Laukien - Chairman of the Board, President, Chief Executive Officer chez Bruker
Actualités
Derniers communiqués de presse par EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- Up and down the ladder: The latest comings and goings
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals appoints Ramiro Ribeiro as chief medical officer (NASDAQ:EYPT)
- Buy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline Outlook
- EyePoint Pharmaceuticals Welcomes New CMO Dr. Ramiro Ribeiro, Eyes Phase 3 Trials
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- EyePoint Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jay Duker 
Appelez EyePoint Pharmaceuticals au +1 617...
